Innate Pharma announces clinical data presentations on IPH5401 and monalizumab at ESMO 2019
Innate Pharma files registration statement for proposed initial public offering in the United States
Innate Pharma reports first half 2019 financial results and business update
Number of shares and voting rights of Innate Pharma as at July 17, 2019
Innate Pharma announces publication of IPH4102 Phase I clinical trial results for CTCL in the Lancet Oncology
Innate Pharma to host key opinion leader call on IPH4102 “TELLOMAK” clinical trial design and rationale
Innate Pharma announces intention to conduct a registered offering in the United States
Innate Pharma to present IPH4102 “TELLOMAK” clinical trial design and preclinical PTCL data at the 2019 ICML
Innate Pharma enrolls first patient in IPH4102 TELLOMAK Phase II study
Innate Pharma announces publication in Cell on innovative multifunctional NKp46 NK cell engagers (NKCEs)
